For decades, physicians relied solely on the three pillars of cancer care — chemotherapy, radiation and surgery — as the cornerstones of oncologic treatment plans. Over the past 20 years, however, a revolution has taken place in the field of oncology as physicians and researchers develop exciting new options for less invasive treatments that offer better results with fewer side effects.
The research efforts of Cynthia Blanco, MD, Medical Director of the Neonatal Nutrition & Bone Institute at University Health System and Professor of Neonatology at UT Health San Antonio, recently helped the medication Omegaven gain FDA approval. The medication, developed by German healthcare company Fresenius Kabi, helps save the lives of infants with parenteral nutrition-associated liver disease.
A multi-institution clinical trial involving researchers from UT Health San Antonio shows significantly lower recurrence of bladder cancer in patients who received the chemotherapy drug gemcitabine.
Immunotherapy is the new frontier in cancer treatment, and researchers at START are at the forefront. START is one of the largest Phase 1 clinical trial organizations in the world.
The UT Medicine Urology physicians treat routine and complex conditions, from kidney stones to rare cancers.
Health care is about the patients. Physicians work for patients. Hospitals work for patients. Treatments are invented, tested and marketed for patients. Patients rely on their physicians and the healthcare system to provide expertise and guidance on which treatment is right for them. However, physicians don’t always know about all the latest treatments available through late-phase clinical trials.
Clinical trials are research studies on human subjects that ultimately allow a drug to enter the market. The ClinZen Clinical Trial Management System (CTMS) is a software system that coordinates these complex trial processes and manages enterprise-level data.
From the Texas Hill Country to San Antonio to South Texas, Cancer Care Centers of South Texas (CCCST) brings state-of-the-art treatments, personalized, compassionate and comprehensive care, and access to clinical trials — close to where patients live and work.